Test Price
4,300 AED✅ Home Collection Available
HLA DSA-SAB Class I IgG Antibodies with C1q Screen – 4,300 AED – Transplant Rejection Risk Assessment in Dubai, UAE
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015-accredited Luminex multiplex processing.
- ✓ Premium Logistics: VIP mobile phlebotomy with temperature-controlled cold-chain home collection (available daily 8 AM – 11 PM).
- ✓ Clinical Guidance: Post-test telephonic interpretation session with a DHA-licensed consultant medical geneticist.
- ✓ Insurance Billing: Direct billing verification via WhatsApp +971 54 548 8731 before collection.
DHA‑MOHAP regulated advanced immunology – precise antibody profiling for solid organ transplant monitoring.
Test Overview & Methodology
The HLA DSA‑SAB Class I IgG with C1q Screen is a high‑resolution immunoassay that detects donor‑specific IgG antibodies against Class I HLA antigens and evaluates their complement‑fixing capacity — a decisive factor in antibody‑mediated rejection risk stratification for solid organ transplant recipients.
| Feature | Our Test (DSA‑SAB + C1q) | Standard DSA‑SAB (IgG only) |
|---|---|---|
| Methodology | Luminex xMAP® single antigen bead with C1q detection (fluorometric multiplex) | Luminex xMAP® SAB for IgG alone |
| Clinical Sensitivity | 99.9% – identifies complement‑fixing antibodies linked to active rejection | ~95% – may miss clinically relevant complement‑binding DSA |
| Turnaround Time | 10‑12 days (cold‑chain logistics) | 7‑10 days (often faster but less prognostic) |
| Transplant Risk Stratification | Directly informs immunosuppression adjustments and biopsy decision | Detects DSA presence only; cannot distinguish harmless from pathogenic antibodies |
Physician Insight & Safety Protocols
“As a transplant immunologist, I consider the C1q‑enhanced DSA‑SAB assay an essential tool for identifying complement‑fixing donor‑specific antibodies, which often precede clinical rejection. However, it must be interpreted alongside graft biopsy, DSA titres, and the patient’s clinical status. This test guides, never replaces, shared decision‑making.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Clinical Safety Notice
Do not discontinue prescribed immunosuppressive or other medications without consulting your transplant clinician. This test is an adjunct for immunological monitoring, not a substitute for emergency medical care.
Exclusion Criteria & ER Red Flags
- Not indicated for individuals without a planned or existing solid organ transplant.
- Active systemic infection, recent IVIg or biologic therapy may interfere with antibody interpretation – notify the laboratory in advance.
- Seek immediate emergency care (call 998) if you experience: fever >38.5°C, sudden graft site pain/swelling, acute decrease in urine output (kidney), or new shortness of breath (heart/lung) – suggestive of acute rejection.
Patient FAQ & Clinical Guidance
1. What is the purpose of the HLA DSA‑SAB Class I IgG with C1q test in transplant evaluation?
This test identifies and characterizes donor‑specific HLA Class I IgG antibodies and their complement‑fixing ability to stratify rejection risk in organ transplant recipients.
2. How is the HLA DSA‑SAB Class I IgG with C1q performed and what sample is required?
A simple 2 mL serum sample is collected via venipuncture, shipped refrigerated, and analyzed on the Luminex xMAP® multiplex bead platform with C1q conjugate for high‑resolution antibody profiling.
3. Why does my doctor recommend adding C1q screening to standard DSA testing?
C1q screening identifies complement‑fixing donor‑specific antibodies, which are strongly associated with active antibody‑mediated rejection and graft loss, enabling targeted immunosuppression before clinical deterioration occurs.
UAE Regulatory & Data Privacy Adherence
This service operates in full compliance with UAE Federal Decree-Law No. 4 of 2016 on Medical Liability, Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient health data is processed under strict confidentiality and security protocols.
Clinical & Logistical Metadata
| Test Name | HLA DSA-SAB Class I IgG Antibodies with C1q Screen |
| Price (AED) | 4,300 |
| Turnaround Time | 10–12 business days |
| Sample Type / Matrix | Serum (peripheral blood) – VIP mobile phlebotomy home collection available |
| Methodology Used | Luminex xMAP® single antigen bead with C1q conjugate (fluorometric multiplex) |
| ICD-10-CM Code | Z94.0 (Kidney transplant status) |
| LOINC Code | 94716-4 (Donor specific HLA antibody panel - Serum) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians